Guardant Health, Inc. (GH)
$162.79-2.79%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $21.6B
- Beta
- 1.58
- P/E (TTM)
- -48.91
- Short % float
- 9.32%
- Days to cover
- 6.2
- SI change
- +8.1%
- 1W
- -13.05%
- 1M
- +3.44%
- vs SPY 1W
- -13.47%
- vs SPY 1M
- +1.38%
Industry peers
FMP comparable companies · ranked by market cap
- NTRABUYNatera, Inc.$56.0BBULLQ 30$390.79-0.73%
- GRALBUYGRAIL Inc.$5.7BRECOVERYQ 67$132.61-2.28%
- BLLNSELLBillionToOne, Inc.$4.4BCRISISQ -10$95.41-5.12%
- PSNLSELLPersonalis, Inc.$1.7BBEARQ 6$16.06-1.25%
- CSTLSELLCastle Biosciences, Inc.$1.0BRECOVERYQ 11$33.71-4.82%
- FLGTBUYFulgent Genetics, Inc.$591MRECOVERYQ 13$20.82-1.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GH?
- LOPJLB’s latest quantitative signal on Guardant Health, Inc. (GH) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GH in?
- Guardant Health, Inc. (GH) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Guardant Health, Inc. (GH) do?
- Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (…